Here’s a great group blog posting on drug pricing, by seven philosophers. The editors of Daily Nous asked seven philosophers, all specialists in ethics, for quick insight into the recent case of Turing Pharmaceuticals, the company that notoriously raised the price of its drug Daraprim from $13.50 to $750.00. The opinions vary widely, although no one has much that’s flattering to say about Turing’s CEO Martin Shkreli. >>>
LINK: Philosophers on Drug Prices (by Nicole Hassoun, Samia Hurst, Chris MacDonald, Jeremy Snyder, Marcel Verweij, Danielle Wenner and Matt Zwolinski for Daily Nous)
The price of Daraprim (pyrimethamine), a drug that treats the parasitic infection toxoplasmosis and is used in some cases to treat cancer and AIDS, was raised from $13.50 to $750.00 per pill when sole rights to its sale in the United States were acquired last month by drug company Turing Pharmaceuticals. The news brought outrage from all corners, prompting the owner of Turing Pharmaceuticals, Martin Shkreli, to announce that the price would be lowered—though he hasn’t said what its new price will be…..
What do you think?
Brought to you by:
Business Ethics Highlights 
Recent Comments